SCHEMBL6824809

SCHEMBL6824809

Cc1cc(-c2[nH]c3ccc(Cl)cc3c2C2=NCCN2)ccc1Cl

nearest known ligand 0.45

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.44
RECQL P46063 1/20 0.44
PTGS2 P35354 7/20 0.43
NISCH Q9Y2I1 3/20 0.42
MAOA P21397 1/20 0.38
MAOB P27338 1/20 0.38
CSF1R P07333 1/20 0.38
MAPT P10636 1/20 0.37
HTR1B P28222 1/20 0.37
HTR2A P28223 1/20 0.37
HTR2C P28335 1/20 0.37
HTR7 P34969 1/20 0.37
HTR3A P46098 1/20 0.37
HTR6 P50406 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7738679 0.99 LMNA (0.46) LMNARECQLPTGS2NISCHMAOA
SCHEMBL6825016 0.87 NISCH (0.51) LMNARECQLPTGS2NISCHCSF1R
SCHEMBL6823645 0.87 LMNA (0.55) LMNARECQLPTGS2NISCHHTR6
Hydrochloric Acid SCHEMBL7736320 0.86 NISCH (0.50) LMNARECQLPTGS2NISCHCSF1R
Hydrochloric Acid SCHEMBL7727169 0.86 LMNA (0.57) LMNARECQLPTGS2NISCHHTR6
SCHEMBL6824458 0.84 NISCH (0.56) LMNARECQLPTGS2NISCHMAOA
SCHEMBL6824740 0.83 LMNA (0.48) LMNARECQLPTGS2NISCHHTR6
SCHEMBL6826340 0.83 PTGS2 (0.50) LMNARECQLPTGS2NISCHMAOA
Hydrochloric Acid SCHEMBL7735661 0.83 NISCH (0.55) LMNARECQLPTGS2NISCHMAOA
SCHEMBL6820932 0.82 PTGS2 (0.52) LMNARECQLPTGS2NISCHCSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040009976-A1 Hypoglycemic imidazoline compounds TAKEUCHI KUMIKO (US) 2004-01-15 US claimed
EP-0924209-B1 Hypoglycemic imidazoline compounds LILLY CO ELI (US) 2003-05-02 EP claimed
EP-1266897-A2 Hypoglycemic imidazoline compounds ELI LILLY AND COMPANY (US) 2002-12-18 EP claimed
US-6410562-B1 ANTIDIABETIC AGENTS ELI LILLY AND COMPANY 2002-06-25 US claimed
EP-0924209-A1 Hypoglycemic imidazoline compounds ELI LILLY AND COMPANY (US) 1999-06-23 EP claimed
US-20040009976-A1 Hypoglycemic imidazoline compounds TAKEUCHI KUMIKO (US) 2004-01-15 US disclosed
EP-0924209-B1 Hypoglycemic imidazoline compounds LILLY CO ELI (US) 2003-05-02 EP disclosed
EP-1266897-A2 Hypoglycemic imidazoline compounds ELI LILLY AND COMPANY (US) 2002-12-18 EP disclosed
US-6410562-B1 ANTIDIABETIC AGENTS ELI LILLY AND COMPANY 2002-06-25 US disclosed
WO-1999032482-A1 HYPOGLYCEMIC IMIDAZOLINE COMPOUNDS ELI LILLY AND COMPANY (US) 1999-07-01 WO disclosed
EP-0924209-A1 Hypoglycemic imidazoline compounds ELI LILLY AND COMPANY (US) 1999-06-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009976-A1 Hypoglycemic imidazoline compounds GPR119, IAPP, GLP1R LMNA 3624/4885RECQL 1979/4885PTGS2 3400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.